7 completed. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
Follow Advanced Malignant Neoplasm: new trials by email Literature Review of Advanced Malignant Neoplasm trials Research Report on Advanced Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer TQB3006 tablets - Advanced Malignant Neoplasm | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 27 | 2024-04-25 | 2025-05-22 |
| A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor TQB3912 tablets - Advanced Malignant Neoplasm | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 36 | 2023-08-16 | 2025-08-11 |
| Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 24 | 2016-03-01 | 2023-06-05 |
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Anakinra, Denosumab, Everolimus - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 57 | 2012-06-19 | 2021-02-25 |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 123 | 2012-05-14 | 2026-08-28 |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, BRAF Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 46 | 2012-02-06 | 2021-01-22 |
| Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Laboratory Biomarker Analysis, Sorafenib Tosylate, Tipifarnib - Advanced Malignant Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 74 | 2005-10-01 | 2017-04-27 |
Neoplasm Metastasis (4) · Neoplasms (3) · Recurrence (3)
Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Neoplasms (1)
Everolimus (2) · Sorafenib (2) · Crizotinib (1) · Denosumab (1) · Interleukin 1 Receptor Antagonist Protein (1) · Receptors, Interleukin-6 (1) · Vemurafenib (1) · tipifarnib (1) · vandetanib (1)
M.D. Anderson Cancer Center (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · National Cancer Institute (NCI) (1) · Wake Forest University Health Sciences (1)
United States (5) · China (2)
Filip Janku (2) · David Hong (1) · Heidi Klepin (1) · Sarina Piha-Paul, MD (1)
PMID 23676418, PMID 25982012, PMID 33867481
P30CA016672 (2), P30CA012197 (1), U01CA062461 (1)